Clinical Trials
26 trialsNCT05379595 2026-06-05
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT06149481 2026-06-05
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06307548 2026-06-05
Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT06710756 2026-06-05
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT07213609 2026-06-05
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
Phase 1/2 Recruiting
NCT07629960 2026-06-05
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Blueprint Medicines Corporation
Phase 1/2 Recruiting
NCT06922383 2026-06-04
A Clinical Study of Arfolitixorin in Patients With mCRC
Isofol Medical AB
Phase 1/2 Recruiting
NCT05319314 2026-06-03
CARABiNER
Lyell Immunopharma, Inc.
Phase 1/2 Recruiting
NCT04083599 2026-06-02
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04956640 2026-05-29
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT06598007 2026-05-29
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Crossignal Therapeutics, Inc.
Phase 1/2 Recruiting
NCT00159484 2026-05-28
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Completed
NCT05919264 2026-05-28
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT07223047 2026-05-28
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT06324357 2026-05-26
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Phase 1/2 Recruiting
NCT04017650 2026-05-22
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05426005 2026-05-22
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Recruiting
NCT06305247 2026-05-20
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Active not recruiting
NCT07540572 2026-05-20
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDEAYA Biosciences
Phase 1/2 Recruiting
NCT07587619 2026-05-20
Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion
University of Southern California
Phase 1/2 Active not recruiting
NCT05726864 2026-05-19
AMPLIFY-7P
Elicio Therapeutics
Phase 1/2 Active not recruiting
NCT04421820 2026-05-18
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07591597 2026-05-18
IGNITE-CRC
National Cancer Center Hospital East
Phase 1/2 Not yet recruiting
NCT05379985 2026-05-15
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT07589517 2026-05-15
DUO-CRC-NK-111
Beijing Biotech
Phase 1/2 Recruiting